



December 18, 2020

**BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

✓ **The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of U.S. FDA approval for the Company's Colesevelam Hydrochloride Tablets, 625 mg, to market a generic equivalent of Welchol® Tablets, 625 mg, of Daiichi Sankyo, Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS - 11973)**

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)

## Lupin Receives Approval for Colesevelam Hydrochloride Tablets

**Mumbai, Baltimore, December 18, 2020:** Pharma major Lupin Limited (Lupin) announced today that it has received approval for its Colesevelam Hydrochloride Tablets, 625 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Welchol® Tablets, 625 mg, of Daiichi Sankyo, Inc.

Colesevelam Hydrochloride Tablets, 625 mg, are indicated as an adjunct to diet and exercise to:

- reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.
- reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).

Colesevelam Hydrochloride Tablets (RLD: Welchol®) had an annual sales of approximately USD 159 million in the U.S. (IQVIA MAT September 2020).

### About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the 3<sup>rd</sup> largest pharmaceutical company in the U.S. by prescriptions and 5<sup>th</sup> in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on Twitter: [www.twitter.com/LupinGlobal](https://www.twitter.com/LupinGlobal) | LinkedIn: [www.linkedin.com/company/lupin/](https://www.linkedin.com/company/lupin/)

Facebook: [www.facebook.com/LupinWorld/](https://www.facebook.com/LupinWorld/)

### For further information or queries please contact –

<p><b>Shweta Munjal</b> Head – Corporate Communications Email: <a href="mailto:shwetamunjal@lupin.com">shwetamunjal@lupin.com</a></p>	<p><b>Arvind Bothra</b> Head – Investor Relations and M&amp;A Email: <a href="mailto:arvindbothra@lupin.com">arvindbothra@lupin.com</a></p>	<p><b>Manjira Sharma</b> General Manager – Corporate Communications Email: <a href="mailto:manjirasharma@lupin.com">manjirasharma@lupin.com</a></p>
---	---	---

#### \*Safe Harbor Statement

Welchol® is a registered trademark of Daiichi Sankyo, Inc.